Published in Anticancer Drugs on October 01, 2003
Anticancer agent shikonin is an incompetent inducer of cancer drug resistance. PLoS One (2013) 0.94
The Phytochemical Shikonin Stimulates Epithelial-Mesenchymal Transition (EMT) in Skin Wound Healing. Evid Based Complement Alternat Med (2013) 0.89
Nec-1 enhances shikonin-induced apoptosis in leukemia cells by inhibition of RIP-1 and ERK1/2. Int J Mol Sci (2012) 0.83
Shikonin enhances efficacy of a gene-based cancer vaccine via induction of RANTES. J Biomed Sci (2012) 0.78
Mechanisms behind the inhibition of lung adenocarcinoma cell by shikonin. Cell Biochem Biophys (2014) 0.77
β-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling. Oncol Lett (2015) 0.75
Shikonin induces apoptosis and inhibits migration of ovarian carcinoma cells by inhibiting the phosphorylation of Src and FAK. Oncol Lett (2014) 0.75
Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells. Oncol Lett (2017) 0.75
[Development of the automated Patlak plot method and its verification in clinical examples]. Nihon Hoshasen Gijutsu Gakkai Zasshi (2007) 0.75
Usefulness of the automatic quantitative estimation tool for cerebral blood flow: clinical assessment of the application software tool AQCEL. Ann Nucl Med (2010) 0.75
[Development of an automatic analytical tool for quantitative cerebral blood flow measurement using 99mTc-ECD, and verification of clinical examples]. Nihon Hoshasen Gijutsu Gakkai Zasshi (2006) 0.75
Semiquantitative measurement of pulmonary hilar gallium-67 uptake using single photon emission computed tomography/computed tomography for the diagnosis of autoimmune pancreatitis. Jpn J Radiol (2010) 0.75